Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
- 17 October 2011
- journal article
- clinical trial
- Published by Wiley in Clinical Transplantation
- Vol. 26 (3) , 447-453
Abstract
Osteopenia and osteoporosis are well-known consequences of allogeneic stem cell transplantation (allo-SCT). The role of prophylactic zoledronic acid on bone turnover following allo-SCT has not been well characterized. We prospectively studied the role of prophylactic use of zoledronic acid on bone metabolism in 17 patients with acute myeloid leukemia (AML) undergoing allo-SCT over a period of three yr (2006-2009). We measured bone mineral density using dual energy X-ray absorptiometry (DXA) scanning and the markers of bone turnover by urinary N-terminal telopeptide (uNTX) and serum osteocalcin levels prior to and serially following transplantation. All patients received 4 mg of zoledronic acid (Zometa, Novartis Pharmaceuticals Corp., Basel, Switzerland) intravenously prior to starting conditioning regimen and at six months after SCT. DXA scores did not change significantly in any patient over time (p > 0.05). uNTX progressively decreased over time (p < 0.001) and serum osteocalcin stabilized after six months. No patient developed osteonecrosis of the jaw. In conclusion, in this prospective pilot study, prophylactic use of zoledronic acid to prevent early bone loss was found to be safe and feasible in patients with AML undergoing allo-SCT during the immediate post-transplantation period.Keywords
This publication has 20 references indexed in Scilit:
- Prospective Assessment of Bone Turnover and Clinical Bone Diseases After Allogeneic Hematopoietic Stem-Cell TransplantationTransplantation, 2010
- The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkAnnals of Oncology, 2009
- Bone loss following hematopoietic stem cell transplantation: a long-term follow-upBlood, 2004
- Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapyThe American Journal of Medicine, 2004
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosisLeukemia, 2001
- Osteoporosis after blood and marrow transplantation: Clinical aspectsTransplantation and Cellular Therapy, 2000
- Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell TransplantationJournal of Bone and Mineral Research, 1999
- Cyclosporin-Ain VitroDecreases Bone Resorption, Osteoclast Formation, and the Fusion of Cells of the Monocyte-Macrophage LineageEndocrinology, 1991
- REDUCED BONE MINERAL DENSITY IN MEN AND WOMEN WITH ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1990